The EGFR-TKIs had a modest response for EGFR mutated lung squamous cell carcinoma patients and might be a selective option for those patients.
No takes yet. Share an insight, caveat, or question.
Zhuang et al. (2017) studied this question.
Synapse has enriched 5 related papers. Consider them for comparative context: